Skip to content

CLYM

Climb Bio, Inc.

NASDAQ · Healthcare · Biotechnology · US

$14.05
−0.07%
Ask drillr

Next report

Analyst consensus

Next report date
Nov 11, 2026
EPS estimate
-$0.19
Revenue estimate

Latest reported

Last report date
Aug 6, 2026
EPS actual
-$0.18
EPS estimate
-$0.21
Revenue actual
Revenue estimate

Track record

Trailing twelve quarters

EPS beats (12Q)
3
EPS misses (12Q)
7
EPS in line (12Q)
0
Avg surprise (4Q)
-3.4%
Revenue beats (12Q)

Analyst ratings

Sell-side consensus

Consensus
Buy
Price target
$27
PT range
$20 – $32
Analysts
7
7 Buy0 Hold0 Sell
Earnings call history

No earnings call summaries available

Reported history
Report dateEPS estimateEPS actualSurpriseRevenue actual
Aug 6, 2026-$0.21-$0.18Beat 14.00%
May 7, 2026-$0.26-$0.20Beat 23.08%
Mar 5, 2026-$0.20-$0.26Miss -31.78%
Nov 6, 2025-$0.16-$0.19Miss -18.75%
May 14, 2025-$0.15-$0.31Miss -106.67%
Mar 25, 2025-$0.15-$0.13Beat 13.33%
Aug 14, 2024-$1.81
May 15, 2024-$0.06
Dec 31, 2023-$0.13-$0.13Miss -2.55%
Sep 30, 2023-$0.14-$0.15Miss -4.70%
Jun 30, 2023-$0.16-$0.19Miss -21.55%
Mar 31, 2023-$0.25-$0.84Miss -236.00%

Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 11, 2026